Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to approximately one year. The trial design was rigorous, including both a blinded treatment phase and a randomized withdrawal period to assess durability of effect. Results from this study contribute direct clinical evidence on whether a standardized full-spectrum cannabis product can serve as a viable pharmacologic option for a condition where current treatments frequently fall short.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited efficacy and significant adverse effect profiles. The large-scale, double-blind design with 820 participants and extended follow-up period establishes a robust foundation for evaluating both efficacy and long-term safety of full-spectrum cannabis extract, potentially offering clinicians a evidence-based alternative to opioids and other conventional analgesics for CLBP management. If positive results are demonstrated, these findings could inform clinical guidelines and regulatory pathways for cannabis-derived medications in musculoskeletal pain,
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents promising data on a full-spectrum cannabis extract for chronic low back pain, a condition where current pharmacologic options remain inadequate for many patients. However, several clinical considerations warrant careful interpretation: the trial’s primary outcomes and effect sizes are not fully detailed in this abstract, the generalizability of results may be limited by participant selection criteria not described here, and long-term safety profiles beyond the study period remain unknown. Additionally, we cannot assess from this summary alone how the extract’s cannabinoid and terpene composition compares to other available products, which could significantly influence both efficacy and tolerability in real-world practice. For clinicians considering cannabis-based interventions for CLBP patients who have failed conventional treatments, this trial provides some supportive evidence, but we should await full publication details and comparative effectiveness data before making firm dosing or strain recommendations, while maintaining careful monitoring for individual variation in response and potential drug interactions.